Is Tesamorelin FDA Approved?
Yes in the United States, for one narrow indication almost nobody quotes. No in the EU, where the application was withdrawn in 2012. The distinction matters.
Tesamorelin sits in an unusual position, and it is the reason it keeps turning up in lists of “FDA-approved peptides” without the sentence that should follow.
It is approved. It has been since 2010. And in the European Union it is not authorised at all, because the application was examined and then withdrawn. Both of those facts are true at the same time, and neither of them is the whole answer to “is tesamorelin approved.”
What the approval actually covers
The United States approval is for the reduction of excess visceral abdominal fat in adults with HIV who have lipodystrophy. That is the entire indication.
Lipodystrophy in this context refers to a redistribution of body fat associated with HIV and, historically, with some antiretroviral regimens. The fat in question is visceral — the deep abdominal fat around the organs — rather than the subcutaneous fat under the skin. The trials that supported approval enrolled that population and measured that outcome.
Tesamorelin is the only medicine approved in the United States for it.
What the approval does not cover is everything else the compound is marketed for in the grey market: general weight loss, body recomposition in people without HIV, athletic performance, growth hormone replacement, or anti-ageing. None of those were the studied question.
An approval is not a certificate that a molecule is safe and effective. It is a finding that a specific product, at a specific dose, in a specific population, for a specific outcome, showed a benefit that outweighed its risks in the evidence submitted. Move any one of those four variables and the finding does not automatically travel with you.
How it works, briefly
Tesamorelin is an analogue of growth hormone-releasing hormone. It does not supply growth hormone. It acts on the pituitary to stimulate the body’s own production of it.
That mechanistic distinction is worth holding onto, because it is the basis of most of the claims made for the compound outside its indication — the reasoning runs “more endogenous growth hormone is better than exogenous growth hormone, therefore it must be better for everything growth hormone is used for.” The first half of that sentence is a reasonable pharmacological observation. The second half is not something the approval speaks to.
The European position
This is the part that gets omitted, and for a reader in the EU it is the part that decides the question.
| Date | What happened |
|---|---|
| November 2010 | FDA approves Egrifta (tesamorelin) in the United States |
| 31 May 2011 | Marketing authorisation application submitted to the EMA |
| July 2012 | Applicant withdraws the application, while under CHMP review |
| March 2025 | FDA approves Egrifta WR (F8 formulation) in the United States |
The withdrawal is not a neutral event. According to the EMA’s own statement, the company withdrew because the CHMP considered that the data provided did not allow it to conclude on a positive benefit-risk balance. The application was in assessment, the assessment was not going well, and it was pulled before a formal negative opinion.
That is a different thing from a drug that was simply never submitted in Europe. The European regulator looked at the evidence and did not reach the same conclusion the American one had.
There is no EU-authorised tesamorelin product today. For anyone in Bulgaria or elsewhere in the Union, the practical consequence is the one that runs through EU medicines law generally: a product that is not authorised is not made lawful by being approved somewhere else.
The three formulations
If you read about tesamorelin, you will encounter three names for what is substantially the same active substance.
Egrifta was the original 2010 product. Egrifta SV was a reformulation. Egrifta WR, based on the F8 formulation, was approved in March 2025 and is intended to replace Egrifta SV.
The difference between them is handling, not pharmacology. The newer formulation moves reconstitution from daily to weekly and requires less than half the injection volume of the one before it.
This matters for a practical reason: older instructions describe older formulations. If you are reading a handling guide written before 2025, it may be describing a product that is being phased out, with a reconstitution schedule that no longer applies.
Why “FDA approved” keeps getting quoted without the rest
Tesamorelin is genuinely one of a very small number of peptides holding a marketing authorisation as a medicine. Our own approval-status overview names it alongside semaglutide and tirzepatide for exactly that reason.
The problem is that “FDA approved” is a phrase that survives being quoted out of context, and the indication does not travel with it. A vial sold on the basis that the compound inside is “FDA approved” is trading on a fact that is true of a prescription product for HIV-associated lipodystrophy, and is not true of the vial.
Approval status attaches to a product, not to a molecule name. The approved product is manufactured under conditions a regulator inspects, labelled with an indication, and dispensed against a prescription. A research-chemical vial shares the name and none of the rest.
The practical part
Tesamorelin is one of the few approved medicines that the person using it reconstitutes themselves. It arrives as a lyophilised powder and becomes a solution in a kitchen, not a pharmacy.
That puts it in the same practical category as every other powder: the arithmetic of concentration applies, the calculator will convert a quantity and a volume into syringe units, and the moment the diluent goes in, a discard window starts running that did not exist while the vial was dry.
The formulation change makes this more consequential rather than less. Moving from daily to weekly reconstitution means a single mixed vial now has to stay correct for longer, and the date it was mixed stops being something you can reconstruct from memory.
Write down the concentration and the date. Those two numbers are what a record has to carry, and they are the two that get lost first.
Frequently asked questions
Is tesamorelin approved by the FDA?
Yes, and it has been since November 2010. But the approval is for one specific indication: the reduction of excess visceral abdominal fat in adults with HIV who have lipodystrophy. It is not approved for general weight loss, for body composition in people without HIV, for athletic performance, or as an anti-ageing treatment. The distinction is not a technicality. An approval attaches to an indication, a population and a dosing regimen that were actually studied — it does not certify the molecule as safe or effective for everything a person might want to use it for. Tesamorelin is the only medicine approved in the United States for that particular indication.
Is tesamorelin approved in the European Union?
No. The marketing authorisation application was submitted to the European Medicines Agency on 31 May 2011 and withdrawn by the applicant in July 2012, while it was still under review by the Committee for Medicinal Products for Human Use. The stated reason was that the CHMP considered the data provided did not allow it to conclude on a positive benefit-risk balance. This is a materially different outcome from an approval that simply never happened — the evidence was examined by the European regulator and found insufficient at that time. There is no EU-authorised tesamorelin product today.
What is the difference between Egrifta, Egrifta SV and Egrifta WR?
They are successive formulations of the same active substance, not different drugs. The original Egrifta was approved in 2010. Egrifta SV followed as a reformulation. Egrifta WR, based on the F8 formulation, was approved in March 2025 and is intended to replace Egrifta SV. The practical difference is administration burden rather than pharmacology: the newer formulation moves reconstitution from daily to weekly and requires less than half the injection volume of its predecessor. If you read older material about tesamorelin, the handling instructions in it may describe a formulation that is being phased out.
Does FDA approval mean tesamorelin is legal to buy for other purposes?
No. An approved medicine is available on prescription for the indication it was approved for, dispensed by a pharmacy. That is a different thing from tesamorelin sold as a research chemical, which is neither the approved product nor subject to the manufacturing controls behind it. Approval status describes a specific product made to a specific standard — it does not transfer to a vial of the same-named substance from an unregulated supplier. In the European Union the question does not even reach that stage, because no authorised tesamorelin product exists there at all.